Extended Data Fig. 3
(A) Data from PBMCs stimulated overnight in ex vivo IFNγ ELISpot with patient-specific peptide pools are shown for all Phase patients with available samples (all except G5). Individual patient IDs legend is shown below graph. Graphs show mean SFU per 106 PBMCs +/- standard deviation (SD) for technical triplicates (ELISpot wells) for all patients and timepoints except for G1 (W20 and W72), G2 (W42), G3 (W0, W5 and W8), G6 (all timepoints), G12 (W12 and W13), G13 (W12), and G14 (all timepoints), where only sufficient cells to test technical duplicates were available. For patient G3 W1 enough cells were available to test a single well. Assay limit of detection (LOD) and upper limit of quantitation (ULOQ) are indicated by dotted lines. ChAd68 boost for patients G1, G3, G8, and G11 are indicated by adenovirus symbol. (B) Longitudinal ELISpot data ≥52 weeks from PBMCs stimulated overnight in ex vivo IFNγ ELISpot with patient-specific CD8 Pools (blue bars) or DMSO (gray bars) are shown for patients G1, G2 and G8. Graphs show mean SFU per 106 PBMCs +/- standard deviation (SD) for triplicate ELISpot wells. (C) ELISpot data (fold change of mean of technical triplicates (all except for G6 (pre and post), G12 & G13 (post), where enough cells to test duplicates were available) are shown for all patients relative to pre-samRNA boost timepoint (week 4, available for all patients except G9), and maximum response post samRNA boost (5-36 week timepoints). Graphs show paired data from patients receiving 30µg samRNA (light blue), 100µg samRNA (medium blue), and 300µg samRNA (navy blue).
